The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
Abstract
Inactivating mutations of the Ten-Eleven Translocation 2 (TET2) gene were first identified in myeloid malignancies and more recently in peripheral T-cell lymphomas (PTCLs). In the present study, we investigated the presence of TET2 coding sequence mutations and their clinical relevance in a large cohort of 190 PTCL patients. TET2 mutations were identified in 40 of 86 (47%) cases of angioimmunoblastic T-cell lymphoma (AITL) and in 22 of 58 (38%) cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), but were absent in all other PTCL entities, with the exception of 2 of 10 cases of enteropathy-associated T-cell lymphoma. Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (TFH) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed TFH markers and/or had features reminiscent of AITL (58% vs 24%, P = .01). In the AITL and PTCL-NOS subgroups, TET2 mutations were associated with advanced-stage disease, thrombocytopenia, high International Prognostic Index scores, and a shorter progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although there was a trend that AITL patients with the pathogenic TET2 mutations detected in the BM/PB had a worse clinical outcome, no statistically significant differences in the second hematologic malignancy-free survival were observed (p-value=0.3273, stratified hazard ratio [HR] = 0.29), consistent with the literature (Lemonnier et al., 2012).”
From Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking (2021) · cites this paper as Lemonnier et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Self-citationFrequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Research works printed but not linked: 19
- Abdel-Wahab, 2009, Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies., Blood, 114, 144, 10.1182/blood-2009-03-210039 · DOI · Paper page
- Tahiliani, 2009, Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1., Science, 324, 930, 10.1126/science.1170116 · DOI · Paper page
- Cimmino, 2011, TET family proteins and their role in stem cell differentiation and transformation., Cell Stem Cell, 9, 193, 10.1016/j.stem.2011.08.007 · DOI
- Quivoron, 2011, TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis., Cancer Cell, 20, 25, 10.1016/j.ccr.2011.06.003 · DOI · Paper page
- Li, 2011, Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies., Blood, 118, 4509, 10.1182/blood-2010-12-325241 · DOI · Paper page
- Couronné, 2012, TET2 and DNMT3A mutations in human T-cell lymphoma., N Engl J Med, 366, 95, 10.1056/NEJMc1111708 · DOI · Paper page
- Vose, 2008, International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes., J Clin Oncol, 26, 4124, 10.1200/JCO.2008.16.4558 · DOI
- Swerdlow, 2008, International Agency for Research on Cancer.
- Dupuis, 2006, Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells., Am J Surg Pathol, 30, 490, 10.1097/00000478-200604000-00009 · DOI
- de Leval, 2007, The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells., Blood, 109, 4952, 10.1182/blood-2006-10-055145 · DOI
- Piccaluga, 2007, Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation., Cancer Res, 67, 10703, 10.1158/0008-5472.CAN-07-1708 · DOI
- de Leval, 2008, Pathobiology and molecular profiling of peripheral T-cell lymphomas., Hematology Am Soc Hematol Educ Program, 2008, 272, 10.1182/asheducation.V2008.1.272.0010272 · DOI
- Rodríguez-Pinilla, 2008, Peripheral T-cell lymphoma with follicular T-cell markers., Am J Surg Pathol, 32, 1787, 10.1097/PAS.0b013e31817f123e · DOI
- Iqbal, 2010, Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma., Blood, 115, 1026, 10.1182/blood-2009-06-227579 · DOI
- Gallamini, 2004, Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study., Blood, 103, 2474, 10.1182/blood-2003-09-3080 · DOI
- Cairns, 2012, IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma., Blood, 119, 1901, 10.1182/blood-2011-11-391748 · DOI
- Pasqualucci, 2011, Inactivating mutations of acetyltransferase genes in B-cell lymphoma., Nature, 471, 189, 10.1038/nature09730 · DOI
- Morin, 2010, Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin., Nat Genet, 42, 181, 10.1038/ng.518 · DOI · Paper page
- Mourad, 2008, Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials., Blood, 111, 4463, 10.1182/blood-2007-08-105759 · DOI
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Vinuesa, C. G., Linterman, M. A., Yu, D., & MacLennan, I. C. M. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055605 · Cited by 1,141
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452
Self-citationUpregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
Shenoy, N., Bhagat, T., Nieves, E., Stenson, M., Lawson, J., Choudhary, G. S., Habermann, T., Nowakowski, G., Singh, R., Wu, X., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.65 · Cited by 111
The European Hematology Association Roadmap for European Hematology Research: a consensus document
Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Dohner, H., de Wit, T. D., Eichinger, S., Fibbe, W., Green, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.136739 · Cited by 81
SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
López-Cobo, S., Fuentealba, J. R., Gueguen, P., Bonté, P.-E., Tsalkitzi, K., Chacón, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1350 · Cited by 72
Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking
Cheng, S., Zhang, W., Inghirami, G., & Tam, W. (2021) · eLife · doi:10.7554/elife.66395 · Cited by 37
Metadata
- Authors
- Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J.-P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R. A., Mak, T., Bastard, C., Bernard, O. A., de Leval, L., & Gaulard, P.
- Affiliations
- Inserm U955, Créteil, France;
- Inserm U985, Institut Gustave Roussy; Université Paris, Villejuif, France;
- Département de Pathologie, Hôpital Pessac, Bordeaux, France;
- Département de Statistiques. Hôpital Necker, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France;
- Département de Pathologie, Hôpital Purpan, Toulouse, France;
- Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Université d'Auvergne, Inserm CIC-501, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Estaing, Clermont-Ferrand, France;
- Département d'Anatomie Pathologique, Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France;
- Département d'Anatomie Pathologique, Hôpital Saint-Antoine, AP-HP, Paris, France;
- Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, Toronto, ON;
- Inserm U918, Université de Rouen, Centre Henri Becquerel, Rouen, France;
- Institut de Pathologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; and
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-08-16
- Volume
- 120
- Issue
- 7
- Pages
- 1466-1469
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 455
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
